|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ARRY 10-Q filed Nov 4, 2008. General and Administrative Expenses General and administrative expenses consist mainly of compensation and associated fringe benefits not included in cost of revenue or research and development for proprietary drug discovery expenses and include other management, business development, accounting, information technology and administration costs, including the establishment and protection of patents, recruiting and relocation, consulting and professional services, travel and meals, sales commissions, facilities, depreciation and other office expenses.
A summary of our general and administrative expenses follows (amounts in thousands):
General and administrative expenses remained consistent with the same period in the prior year.
This excerpt taken from the ARRY 10-K filed Aug 15, 2008. General and Administrative Expenses General and administrative expenses consist mainly of compensation and associated fringe benefits not included in cost of revenue or research and development for proprietary drug discovery expenses and include other management, business development, accounting, information technology and administration costs, including patent prosecution, recruiting and relocation, consulting and professional services, travel and meals, sales commissions, facilities, depreciation and other office expenses.
42
A summary of our general and administrative expenses follows (amounts in thousands):
This excerpt taken from the ARRY 10-Q filed May 5, 2008. General and Administrative
Expenses. Total general and administrative expenses, as
compared to the prior year periods, were as follows:
The increase in general and administrative expenses of approximately $467,000 and $3.4 million during the three and nine months ended March 31, 2008, respectively, over the prior year were primarily the result of
22
increased spending in patent-related expenses of approximately $144,000 and $1.5 million, for the respective periods. As discussed above under Future Outlook, we do not expect patent-related expenses to increase significantly during the remainder of fiscal 2008. In addition, compensation and benefit related expenses increased by approximately $217,000 and $927,000 for the three- and nine-month periods, respectively, due to the addition of general and administrative personnel. Expenses incurred for professional services increased by approximately $252,000 and $933,000 for the three- and nine-month periods, respectively, due to increased audit fees related to accounting for income taxes, general legal matters associated with expansion of our clinical trials, and other costs associated with new corporate systems and human resources consulting. We do not expect that these increases will continue with the exception of legal expenses as we continue to expand our clinical relationships with clinical research organizations.
This excerpt taken from the ARRY 10-Q filed Feb 5, 2008. General and Administrative Expenses. Total general and administrative
expenses, as compared to the prior year periods, were as follows:
General and administrative expenses increased by approximately $1.5 million and $3.0 million, respectively, during the three and six months ended December 31, 2007 compared to the same periods in the prior year. The increase was primarily the result of increased spending in patent-related expenses of approximately $1.1 million and $1.3 million, for the three and six months ended December 31, 2007, respectively. As discussed above under Future Outlook, we do not expect patent-related expenses to continue to increase during the second half of fiscal 2008. In
20
addition, compensation and benefit related expenses also increased by approximately $400,000 and $700,000 for the three- and six-month periods, respectively. For the three and six months ended December 31, 2007 audit, legal, and consulting expenses increased by approximately $110,000 and $580,000, respectively.
This excerpt taken from the ARRY 10-Q filed Nov 6, 2007. General and Administrative
Expenses. Total
general and administrative expenses, as compared to the prior year period, were
as follows:
General and administrative expenses increased by $1.4 million, or 47%, during the three months ended September 30, 2007 compared to the same period in the prior year. The increase was primarily the result of increased spending in audit, legal and consulting expenses of approximately $470,000. Also contributing were increases in compensation and benefit related expenses of approximately $300,000, as well as increased patent related expenses of approximately $250,000.
This excerpt taken from the ARRY 10-K filed Sep 13, 2007. General and Administrative Expenses General and administrative expenses consist mainly of compensation and associated fringe benefits not included in cost of revenue or research and development expenses and include other management, business development, accounting, information technology and administration costs, including patent prosecution, recruiting and relocation, consulting and professional services, travel and meals, advertising, sales commissions, facilities, depreciation and other office expenses.
Fiscal 2007 as compared to Fiscal 2006: General and administrative expenses decreased by approximately $145,000 during the 2007 fiscal year over the prior fiscal year primarily as a result of decreased share-based compensation expense of approximately $790,000 recognized upon the vesting of option shares in the prior fiscal year. As described in cost of revenue above, the change in estimated useful life of our leasehold improvements resulted in a reduction of amortization of leasehold improvement costs charged to general and administrative expenses for the 2007 fiscal year of approximately $90,000 and the reversal of the prior year deferred rent balance resulted in a reduction to rent expense allocated to general and administrative expenses for the 2007 fiscal year of approximately $150,000. Partially offsetting all these decreases in general and administrative expenses were increases in patents and patent application costs of approximately $830,000 for the 2007 fiscal year associated with the advancement of our propriety drug development programs. The remaining increase in general and administrative expenses from the prior year was attributable to increases in compensation and benefit expenses. Fiscal 2006 as compared to Fiscal 2005: The increase in general and administrative expenses for fiscal 2006 over fiscal 2005 was primarily related to the recording of $2.7 million of share-based compensation expense in accordance with SFAS 123(R). Patents and patent application costs increased by approximately $353,000 related to our expanding proprietary drug development programs. In addition, as described in cost of revenue above, we recorded approximately $132,000 of additional leasehold improvement amortization to general and administrative expenses during the 2006 fiscal year. The remaining increase within general and administrative expenses from the prior year was attributable to increases in compensation and benefit related expenses. | EXCERPTS ON THIS PAGE:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
